CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Revenues:
Total revenues	$ 106,275	$ 229,504
Costs and expenses:
Cost of sales (excluding amortization of intangible assets)	19,872	9,505
Research and development expenses	4,213	10,106
Selling, general and administrative expenses	104,324	108,866
Amortization of intangible assets	24,783	101,774
Loss on impairment of goodwill and intangible assets	17,432	189,790
Restructuring charges	17,806	3,891
Total costs and expenses	188,430	423,932
Loss from operations	(82,155)	(194,428)
Other income (expense):
(Loss) Gain on debt extinguishment	(56,113)	26,385
Interest expense	(15,926)	(58,389)
Other (loss) gain	(3,225)	3,948
Total other income (expense)	36,642	(28,056)
Net loss before income taxes	(45,513)	(222,484)
Income tax benefit	17,369	5,283
Net loss	(28,144)	(217,201)
Comprehensive loss	$ (28,144)	$ (217,201)
Basic net loss per share (in dollars per share)	$ (0.27)	$ (3.07)
Diluted net loss per share (in dollars per share)	$ (0.27)	$ (3.07)
Shares used in computing basic net loss per share (in shares)	104,835	70,716
Shares used in computing diluted net loss per share (in shares)	104,835	70,716
Product sales, net
Revenues:
Total revenues	$ 93,498	$ 108,806
Commercialization agreement, net
Revenues:
Total revenues	11,258	118,614
Royalties and milestones
Revenues:
Total revenues	1,519	2,084
NUCYNTA
Other income (expense):
Gain (loss) on sale	(14,749)	0
Gralise
Revenues:
Total revenues	300	63,100
Other income (expense):
Gain (loss) on sale	$ 126,655	$ 0